UK Markets close in 6 hrs 7 mins

AC Immune SA (ACIU)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.99000.0000 (0.00%)
At close: 04:00PM EDT
3.0900 +0.10 (+3.34%)
After hours: 05:28PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.9900
Open2.8600
Bid0.0000 x 900
Ask0.0000 x 1100
Day's range2.8600 - 3.0500
52-week range2.4600 - 12.6100
Volume237,910
Avg. volume93,556
Market cap217.232M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.0700
Earnings date26 Apr 2022 - 02 May 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est12.71
  • Globe Newswire

    AC Immune’s Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology

    First study of an anti-Abeta vaccine in people living with Down syndrome (DS) Immune response and Alzheimer’s disease (AD) biomarkers showed positive impact of ACI-24 first generation vaccine Optimized formulation of the ACI-24 vaccine to enter Phase 1b/2 testing this year LAUSANNE, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced the publ

  • Globe Newswire

    AC Immune Reports First Quarter 2022 Financial Results and Provides Corporate Update

    Two clinical readouts delivered in Q1; five more expected by year-end Interim data from the Phase 1b/2a trial of ACI-35.030 confirm the favorable safety and potent immunogenicity of this first-in-class anti-pTau vaccine First images of alpha-synuclein in patients’ brains presented at AD/PDTM Conference provide clinical proof-of-concept for ACI-12589 as a PET tracer for alpha-synucleinopathies (e.g. MSA) Strong financial position of CHF 173.8 million ensures the Company is fully financed through

  • Globe Newswire

    AC Immune to Present at the B. Riley Annual Neuro & Ophthalmology Virtual Investor Conference

    LAUSANNE, Switzerland, April 27, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will participate in a Fireside chat and one-on-one investor meetings during the B.Riley Annual Neuro & Ophthalmology Virtual Investor Conference, taking place virtually on April 27-28, 2022. During the Fireside chat, Prof. Andrea Pfeifer, CEO, AC Immune SA, will discu